Author:
Sugino Keishi,Kabuki Takayuki,Shibuya Kazutoshi,Homma Sakae
Reference6 articles.
1. An open-label, Phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial;Khanna;J Rheumatol,2016
2. Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?;Kovacs;Arthritis Res Ther,2015
3. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma;Kovacs;Am J Respir Crit Care Med,2009
4. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease;Miura;Sarcoidosis Vasc Diffuse Lung Dis,2014
5. A case report: the efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: a CARE-compliant article;Huang;Medicine,2016